News | Artificial Intelligence

May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National ...

Home May 12, 2021
Home
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
News | Heart Failure

May 11, 2021 — Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a ...

Home May 11, 2021
Home
Videos | Structural Heart

Philippe Géneréux, M.D., director of the structural heart program at Atlantic Health System’s Morristown Medical Center ...

Home May 10, 2021
Home
News | Wearables

May 10, 2021 – Today, the Consumer Technology Association (CTA) announced it is collaborating with the American College ...

Home May 10, 2021
Home
News | Artificial Intelligence

May 10, 2021 — Eko announced the peer-reviewed publication of a clinical study that found that the Eko artificial ...

Home May 10, 2021
Home
Videos | Radial Access

Arnold Seto, M.D., MPA, FSCAI, chief of cardiology, Long Beach Veterans Affairs Medical Center and director ...

Home May 06, 2021
Home
Videos | Coronavirus (COVID-19)

Payam Dehghani, M.D., FRCPC, FACC, FSCAI, co-director of Prairie Vascular Research and associate professor at the ...

Home May 06, 2021
Home
News | Wearables

May 6, 2021 — The wearable cardiac devices market is set to grow from its current market was valued at more than $1.2 ...

Home May 06, 2021
Home
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
News | EP Lab

May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.  Christoper Baker, M.D., Hoag Memorial Hospital using the system. #SCAI21 #SCAI2021
Feature | Robotic Systems

May 5, 2021 — A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic ...

Home May 05, 2021
Home
News | Cardiovascular Business

May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) ...

Home May 05, 2021
Home
Subscribe Now